CompletedPhase 2NCT01111305
Reslizumab to Prevent Post-treatment Eosinophilia in Loiasis
Studying Loiasis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- Principal Investigator
- Amy D Klion, M.D.National Institute of Allergy and Infectious Diseases (NIAID)
- Intervention
- Reslizumab(drug)
- Enrollment
- 31 enrolled
- Eligibility
- 18-65 years · All sexes
- Timeline
- 2010 – 2017
Study locations (1)
- National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01111305 on ClinicalTrials.govOther trials for Loiasis
Additional recruiting or active studies for the same condition.